Regenicin Financials
| RGIN Stock | USD 0.0001 0.00 0.00% |
Regenicin |
Regenicin Stock Summary
Regenicin competes with Denali Therapeutics, Cardiff Oncology, Cytodyn, Inovio Pharmaceuticals, and Mustang Bio. Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey. Regenicin operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US75887Q1022 |
| Business Address | 10 High Court, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.regenicin.com |
| Phone | 973 557 8914 |
| Currency | USD - US Dollar |
Regenicin Key Financial Ratios
Regenicin's financial ratios allow both analysts and investors to convert raw data from Regenicin's financial statements into concise, actionable information that can be used to evaluate the performance of Regenicin over time and compare it to other companies across industries.| Return On Asset | -37.38 | |||
| Beta | -1.79 |
Regenicin Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Regenicin's current stock value. Our valuation model uses many indicators to compare Regenicin value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Regenicin competition to find correlations between indicators driving Regenicin's intrinsic value. More Info.Regenicin is currently regarded as top stock in return on asset category among its peers. It also is currently regarded number one company in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Regenicin by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Regenicin's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Regenicin Systematic Risk
Regenicin's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Regenicin volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Regenicin correlated with the market. If Beta is less than 0 Regenicin generally moves in the opposite direction as compared to the market. If Regenicin Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Regenicin is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Regenicin is generally in the same direction as the market. If Beta > 1 Regenicin moves generally in the same direction as, but more than the movement of the benchmark.
Other Information on Investing in Regenicin Pink Sheet
Regenicin financial ratios help investors to determine whether Regenicin Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Regenicin with respect to the benefits of owning Regenicin security.